Aranesp, Procrit Reimbursement Support Could Raise Kickback Issues – IG
Executive Summary
An IG advisory opinion rejecting a proposed patient support program for Aranesp (darbepoetin) helps clarify limits of competition in the chronic renal failure market, Amgen maintains
You may also be interested in...
J&J Wants Changes To Medicare OPPS Rule; Procrit Could Benefit
Johnson & Johnson is hoping for changes in the proposed 2003 Medicare Outpatient Prospective Payment System that would even out reimbursement differences between Procrit (epoetin) and Amgen's Aranesp (darbepoetin)
J&J Eprex Stability Improvements Planned In Response To Aplasia Incidence
Johnson & Johnson will seek alternative stabilizers for its erythropoietin Eprex in response to reports of pure red cell aplasia following the removal of human serum albumin from the product formula
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011